Text Size

Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
The Cleveland Clinic
ClinicalTrials.gov Identifier:
NCT00599118
First received: January 10, 2008
Last updated: June 1, 2010
Last verified: June 2010
History of Changes
  Purpose

The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.


Condition
Atrial Fibrillation

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:
  • Atrial fibrillation [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Stroke [ Time Frame: 4 years ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

plasma, serum, buffy coat, DNA


Estimated Enrollment: 1300
Study Start Date: August 2005
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts
atrial fibrillation
Atrial fibrillation
Control
Control subjects with no atrial fibrillation

Detailed Description:

Blood samples and data will be collected from subjects with atrial fibrillation and normal controls. The primary aim of future research using these samples is to identify mechanisms and pathogenesis of atrial fibrillation. Through this information, we hope to identify targets for new therapies and improve knowledge and understanding of atrial fibrillation. Identification of disease genes could improve strategies that prevent progression of atrial fibrillation to more persistent disease.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Subjects with atrial fibrillation

Criteria

Inclusion Criteria for Atrial Fibrillation group:

  • Male or female at least 18 years old
  • Subjects with a history of or current Atrial Fibrillation
  • Subjects able to give informed consent

Inclusion Criteria for Controls:

  • Male or female at least 18 years old
  • Subjects with no history of Atrial Fibrillation
  • Subjects able to give informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00599118

Locations
United States, Ohio
Cleveland Clinical Foundation
Cleveland, Ohio, United States, 44145
Sponsors and Collaborators
The Cleveland Clinic
Investigators
Principal Investigator: Mina K Chung, MD The Cleveland Clinic
  More Information

No publications provided

Responsible Party: Mina K. Chung, MD, Cleveland Clinic Foundation
ClinicalTrials.gov Identifier: NCT00599118     History of Changes
Other Study ID Numbers: 8271
Study First Received: January 10, 2008
Last Updated: June 1, 2010
Health Authority: United States: Institutional Review Board

Keywords provided by The Cleveland Clinic:
Atrial Fibrillation
Genetics

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on May 19, 2013